An Overview of Heat Shock Protein 27 (Hsp27) Inhibition and the Mechanism of Action of OGX-427
OGX-427 is designed to inhibit Heat Shock Protein 27 (HSP27), a cell-survival protein found at elevated levels in many human cancers including prostate, bladder, breast and non-small cell lung cancer. Overexpression of Hsp27 is thought to be an important factor leading to the development of treatment resistance and is associated with negative clinical outcomes in patients with various tumor types.
The “ORCA” (Ongoing studies evaluating treatment Resistance in CAncer) program encompasses clinical studies of OGX-427, aiming to demonstrate that inhibition of Hsp27 can lead to improved prognosis and treatment outcomes for cancer patients.
Learn more about OGX-427 Clinical Trial Results.
Clinical Development Program
Borealis-1: OGX-427 in Metastatic Bladder Cancer
Borealis-2: OGX-427 in Metastatic Bladder Cancer
OGX-427-BL01: OGX-427 in Superficial Bladder Cancer
Pacific: OGX-427 in Advanced Prostate Cancer
OGX-427-PR01: OGX-427 in Advanced Prostate Cancer
Spruce:OGX-427 in Advanced Non-Squamous, Non-Small Cell Lung Cancer (NSCLC)
Cedar: OGX-427 In Advanced Squamous Non-Small Cell Lung Cancer (NSCLC)
Rainier: OGX-427 in Metastatic Pancreatic Cancer
This section is intended specifically for healthcare professionals. Information is provided for educational use only, based on pre-clinical and clinical data of OGX-427.
OGX-427 is not approved for commercial use and is only available for investigational use in approved clinical trials.